OSE IMMUNOTHERAPEUTICS

NAME OF THE CEO
Alexis PEYROLES

EMAIL
Sylvie.detry@ose-immuno.com
www.ose-immuno.com

ADDRESS
22 bd Benoni Goullin,
44200 Nantes

MISSION
OSE Immunotherapeutics is a biotechnology company focused on the development of innovative immunotherapies for immune activation and regulation in the fields of immuno-oncology and autoimmune diseases.

TECHNOLOGY
The company has several scientific and technological platforms: neoepitopes, agonist or antagonist monoclonal antibodies, ideally positioned to fight cancer and autoimmune diseases.

COMPETITION
Immuno-oncology: chemotherapies, checkpoint inhibitors (CKI)/combinations CKI/CKI – CKI/therapeutic vaccines, targeted therapies
Auto-immune diseases: corticoids, immunosuppressors, immunomodulators, anti-TNFα

ALLIANCES/PARTNERSHIPS
A global license and collaboration agreement with Boehringer Ingelheim (April 2018) to develop checkpoint inhibitor OSE-172 (anti-SIRPa monoclonal antibody), for the treatment of advanced solid tumors.
A license agreement with Janssen Biotech (July 2016) to continue clinical development of FR104 (an anti CD28 mAb) in auto-immune diseases after positive phase 1 results.
A 2-step license option with Servier Laboratories (December 2016) to develop OSE-127 (monoclonal antibody targeting the CD127 receptor, the alpha chain of the interleukin-7 receptor) to develop the product up to the completion of a phase 2 clinical trial planned in autoimmune bowel disease and Sjogren disease.

UPCOMING CATALYSTS
Major immuno-oncology programs addressing unmet needs:
- Tedopi®: Phase 3 ongoing
- OSE-172: en route to Phase 1 (end of 2018)
- OSE-703: pre-clinical in solid tumor / NSCLC
A potential of €1.5 B milestone payments in auto-immune diseases and in immuno-oncology through partnerships with top pharmaceuticals
Additional first-in-class products in discovery/early clinical covering immuno-oncology (Myeloid Checkpoints) and auto-immune indications.

MARKET FIGURES (listed companies)
Revenues 2017:
As of December 31, 2017:
- €6.7 million turnover
- Cash available of €12.5 million, not including the 2016 & 2017 research tax credits of €5.5 million planned S1 2018.
Date of IPO: 30 March 2015
Ticker: OSE
Exchange: Euronext Paris
Currency: €
Market cap: 65M€
Price: €4.21
52-weeks-high: €7.05
52-weeks-low: €3.23
Average daily volume: EURm 0.1
OSE IMMUNOTHERAPEUTICS

NAME OF THE CEO
Alexis PEYROLES

ADDRESS
22 bd Benoni Goullin,
44200 Nantes

EMAIL
Sylvie.detry@ose-immuno.com
www.ose-immuno.com

MANAGEMENT TEAM
CEO: Alexis Peyroles
CFO: Anne-Laure Autret-Cornet
CSO or CTO: Nicolas Poirier
IRO: NA

TARGETED MARKET
Immuno-oncology
Auto-immune diseases

LISTED COMPANY

CREATION DATE
April 2012

KEY FIGURES

<table>
<thead>
<tr>
<th>In k€</th>
<th>12/31/2017</th>
<th>12/31/2016</th>
</tr>
</thead>
<tbody>
<tr>
<td>Current operating result</td>
<td>-12 626</td>
<td>-8 236</td>
</tr>
<tr>
<td>Operating result</td>
<td>-12 626</td>
<td>17 499</td>
</tr>
<tr>
<td>Net result</td>
<td>-10 503</td>
<td>20 666</td>
</tr>
<tr>
<td>Available cash*</td>
<td>12 528</td>
<td>17 766</td>
</tr>
<tr>
<td>Consolidated balance sheet</td>
<td>77 353</td>
<td>89 547</td>
</tr>
</tbody>
</table>

ANALYST COVERAGE

<table>
<thead>
<tr>
<th>Broker</th>
<th>Date</th>
<th>Reco. (buy/neutral/hold)</th>
<th>Target Price</th>
<th>Potential (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kepler Cheuvreux</td>
<td>6 April 2018</td>
<td>Buy</td>
<td>€9.00</td>
<td>+ 97.8</td>
</tr>
<tr>
<td>Invest Securities</td>
<td>6 April 2018</td>
<td>Buy</td>
<td>€11.00</td>
<td>+ 215</td>
</tr>
<tr>
<td>Average:</td>
<td>-</td>
<td>-</td>
<td>€10.00</td>
<td></td>
</tr>
</tbody>
</table>

SHAREHOLDERS (percentage)

Free float = 52%

PIPELINE

<table>
<thead>
<tr>
<th>PROGRAM</th>
<th>Indication</th>
<th>Humanized lead</th>
<th>Pre-Clinical POC</th>
<th>Phase 1</th>
<th>Phase 2</th>
<th>Phase 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>IMMUNO-ONCOTOLOGY</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tedopi®</td>
<td>NSCLC</td>
<td>Advanced pancreatic</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tedopi®</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>OSE-172</td>
<td>Various cancers</td>
<td></td>
<td>2018</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>OSE-703</td>
<td>Various cancers</td>
<td></td>
<td>2018</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AUTO IMMUNE DISEASES</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FR104</td>
<td>Rheumatoid arthritis</td>
<td></td>
<td></td>
<td>2018</td>
<td></td>
<td></td>
</tr>
<tr>
<td>OSE-127</td>
<td>Lymphoma</td>
<td></td>
<td></td>
<td></td>
<td>2018</td>
<td></td>
</tr>
</tbody>
</table>

+ First-in-class products